このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Sernova マネジメント

マネジメント基準チェック /14

現在、CEO に関する十分な情報がありません。

主要情報

Cynthia Pussinen

最高経営責任者

CA$2.6m

報酬総額

CEO給与比率	3.6%
CEO在任期間	less than a year
CEOの所有権	n/a
経営陣の平均在職期間	less than a year
取締役会の平均在任期間	5.4yrs

経営陣の近況

Recent updates

Here's Why We're Not At All Concerned With Sernova's (CVE:SVA) Cash Burn Situation

Feb 23

We Think Sernova (CVE:SVA) Can Easily Afford To Drive Business Growth

Aug 11

CEO報酬分析

Sernova の収益と比較して、Cynthia Pussinen の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Apr 30 2024	n/a	n/a	-CA$41m
Jan 31 2024	n/a	n/a	-CA$41m
Oct 31 2023	CA$3m	CA$92k	-CA$39m

報酬と市場: Cynthiaの総報酬 ($USD 1.88M ) は、 Canadian市場 ($USD 175.38K ) の同規模の企業の平均を上回っています。

報酬と収益: Cynthiaの報酬と会社の業績を比較するにはデータが不十分です。

CEO（最高経営責任者

Cynthia Pussinen

less than a year

在職期間

CA$2,574,600

報酬

Ms. Cynthia Pussinen is Chief Executive Officer & Director at Sernova Corporation from September 2023. She served as an Executive Vice President of Technical Operations and Supply Chain at Actinium Pharmac...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Cynthia Pussinen	CEO & Director	less than a year	CA$2.57m	データなし
Modestus Obochi	Chief Business Officer	less than a year	CA$996.01k	データなし
Frank Shannon	Vice President of Clinical Development & Regulatory Affairs	2.8yrs	CA$463.26k	データなし
Nicholas Rossettos	Interim Chief Financial Officer	less than a year	データなし	データなし
Douglas Maret	Chief Science Officer	no data	データなし	データなし
Christopher Barnes	Vice President of Investor Relations	2.5yrs	CA$352.33k	データなし

0.8yrs

平均在職期間

経験豊富な経営陣: SVAの経営陣は経験豊富とはみなされません ( 0.8年の平均在職年数)。これは新しいチームを示唆しています。

取締役

名称	ポジション	在職期間	報酬	所有権
Cynthia Pussinen	CEO & Director	less than a year	CA$2.57m	データなし
James Parsons	Independent Director	12.2yrs	CA$183.27k	0.094% CA$ 94.0k
Norman C. Wong	Member of Scientific Advisory Board	17.9yrs	データなし	データなし
Jannette Dufour	Member of Scientific Advisory Board	17.8yrs	データなし	データなし
George King	Member of Scientific Advisory Board	no data	データなし	データなし
Clive Patience	Member of Scientific Advisory Board	17.5yrs	データなし	データなし
Brett Whalen	Independent Chairman	1.2yrs	CA$170.23k	0.87% CA$ 874.5k
Steven Paraskevas	Member of Scientific Advisory Board	13.5yrs	データなし	データなし
David Lillicrap	Member of Scientific Advisory Board	5.4yrs	データなし	データなし
Anke Schulte	Member of Global Advisory Board	3.9yrs	データなし	データなし
Stephen Sangha	Independent Director	1.2yrs	CA$158.36k	4.01% CA$ 4.0m
Sam Wiseman	Member of Scientific Advisory Board	3.2yrs	データなし	データなし

5.4yrs

平均在職期間

59yo

平均年齢

経験豊富なボード: SVAの取締役会は経験豊富であると考えられます ( 5.4年の平均在任期間)。

Sernova マネジメント

マネジメント 基準チェック /14

主要情報

経営陣の近況

Sernova Corp. Appoints Jonathan Rigby to Board of Directors

Sernova Corp., Annual General Meeting, Apr 30, 2024

Sernova Corp. Appoints Cynthia Pussinen as Chief Executive Officer

Chairman recently bought CA$238k worth of stock

Sernova Corp Appoints Modestus Obochi as Chief Business Officer

Sernova Corp. Announces Executive Changes

Recent updates

Sernova Corp. Appoints Jonathan Rigby to Board of Directors

New minor risk - Share price stability

New minor risk - Market cap size

Price target decreased by 13% to CA$3.53

Sernova Corp., Annual General Meeting, Apr 30, 2024

New minor risk - Financial position

Companies Like Sernova (TSE:SVA) Are In A Position To Invest In Growth

Sernova Corp. Announces New Advancements of Conformal Coating Technology in Combination with the Cell Pouch System™ at the 2023 IPITA-IXA-CTRMS Joint Congress

Sernova Announces Positive Ongoing Interim Phase 1/2 Clinical Data for the Cell Pouch System™ for Type 1 Diabetes Trial at the 2023 IPITA, IXA, and CTRMS Joint Congress

Sernova Corp. Announces New Preclinical Data for its Novel Cell Therapy Platform, Cell Pouch System, as Potential Treatment for Post-Operative Hypothyroidism at 2023 American Thyroid Association Annual Meeting

Price target decreased by 16% to CA$3.52

Sernova Corp. Provides Development Update on Proprietary Cellular Conformal Coating Technology in Combination with Cell Pouch Device

Sernova Corp. Appoints Cynthia Pussinen as Chief Executive Officer

We're Keeping An Eye On Sernova's (TSE:SVA) Cash Burn Rate

Chairman recently bought CA$238k worth of stock

Sernova Corp Appoints Modestus Obochi as Chief Business Officer

Sernova Corp. Announces Positive Updated Interim Phase 1/2 Clinical Data for the Cell Pouch System™? at American Diabetes Association 83rd Scientific Sessions

New major risk - Financial position

Sernova Corp. Announces Executive Changes

Less than half of directors are independent

We Think Sernova (TSE:SVA) Can Afford To Drive Business Growth

Sernova Corp., Annual General Meeting, Apr 27, 2023

Sernova Announces Advancements with Its Novel Cell Pouch System™ to Preserve Thyroid Function Following Total Thyroidectomy

Sernova Corp. Announces Executive Changes

Sernova Announces First Two Patients Implanted with Cell Pouch™ in the Second Cohort of Its US Phase 1/2 Clinical Trial for Type 1 Diabetes

Price target increased to CA$4.21

Sernova Receives Authorization to Enroll Second Patient Cohort of Phase 1/2 Trial with Cell Pouch System™ for Type 1 Diabetes

We Think Sernova (TSE:SVA) Can Afford To Drive Business Growth

Sernova Corp. Appoints Daniel Mahony, Ph.D. to Its Board of Directors, Effective from September 30, 2022

Executive Chairman of the Board recently bought CA$65k worth of stock

Sernova Corp. Announces Positive Updated Phase 1/2 Clinical Data on Cell Pouch System Tm at American Diabetes Association 82nd Scientific Sessions 2022

Sernova Corp.(TSXV:SVA) dropped from S&P/TSX Venture Composite Index

Sernova Corp. announced that it has received CAD 20.323499 million in funding from Evotec SE

Sernova Announces Abstract on Phase 1/2 Trial with Cell Pouch Selected for Oral Podium Presentation At American Diabetes Association 82Nd Scientific Sessions 2022

No longer forecast to breakeven

Here's Why We're Not At All Concerned With Sernova's (CVE:SVA) Cash Burn Situation

Sernova Corp., Annual General Meeting, Apr 28, 2022

Sernova Corp. Announces Publication of A Peer Reviewed Preclinical Study Demonstrating Positive Results of A Novel Cell Pouch System Cell Therapy

Sernova Corp. Provides Progress Update on Its Phase 1/2 T1d Clinical Trial

Sernova to Announce New Interim Results of its Type 1 Diabetes Clinical Trial During the 40th Annual J.P. Morgan Healthcare Conference

Sernova Announces Clinical Investigator Update of its Type 1 Diabetes Trial at the 2022 ASTS 22nd Annual Winter Symposium

Forecast to breakeven in 2024

We Think Sernova (CVE:SVA) Can Easily Afford To Drive Business Growth

Sernova's Principal Investigator Presents Positive New Data from Ongoing Type 1 Diabetes (T1D) Clinical Trial at ATC 2021 Virtual Connect Conference

Chief Financial Officer recently bought CA$78k worth of stock

Sernova Corp. has completed a Composite Units Offering in the amount of CAD 20.04 million.

Sernova Corp Announces Second Annual Data Safety Monitoring Board Review of its Diabetes Cell Pouch System Clinical Trial and Recommendation for Protocol Continuation

Independent Chairman exercised options to buy CA$272k worth of stock.

Sernova Corp. Announces Collaboration Agreements with Multiple Pharmaceutical Industry Leaders

New 90-day high: CA$0.75

New 90-day high: CA$0.57

New 90-day high: CA$0.31

Sernova Corp. Provides Clinical Update on U.S. Phase I/II Cell Pouch Trial for Type 1 Diabetes

New 90-day low: CA$0.26

Sernova Corp. announced that it has received CAD 3.6655 million in funding

Sernova Corp. announced that it expects to receive CAD 3 million in funding

CEO報酬分析

CEO（最高経営責任者

在職期間

報酬

リーダーシップ・チーム

平均在職期間

取締役

平均在職期間

平均年齢

マネジメント基準チェック /14